LeonaBio, Inc. (LONA) - Total Assets
Based on the latest financial reports, LeonaBio, Inc. (LONA) holds total assets worth $92.15 Million USD as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See what is LeonaBio, Inc.'s book value for net asset value and shareholders' equity analysis.
LeonaBio, Inc. - Total Assets Trend (2018–2025)
This chart illustrates how LeonaBio, Inc.'s total assets have evolved over time, based on quarterly financial data.
LeonaBio, Inc. - Asset Composition Analysis
Current Asset Composition (December 2025)
LeonaBio, Inc.'s total assets of $92.15 Million consist of 97.1% current assets and 2.9% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 75.2% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2018–2025)
This chart illustrates how LeonaBio, Inc.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see LONA market cap.
Key Asset Composition Facts
- Current vs. Non-Current Assets: LeonaBio, Inc.'s current assets represent 97.1% of total assets in 2025, a decrease from 99.3% in 2018.
- Cash Position: Cash and equivalents constituted 75.2% of total assets in 2025, up from 67.2% in 2018.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2018.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
LeonaBio, Inc. Competitors by Total Assets
Key competitors of LeonaBio, Inc. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Fortress Biotech Inc
NASDAQ:FBIO
|
USA | $185.55 Million |
|
Summit Therapeutics PLC
NASDAQ:SMMT
|
USA | $261.73 Million |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
Apellis Pharmaceuticals Inc
NASDAQ:APLS
|
USA | $1.08 Billion |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
BrightGene Bio Medical Technology C
SHG:688166
|
China | CN¥5.38 Billion |
|
BioArctic AB (publ)
ST:BIOA-B
|
Sweden | Skr2.60 Billion |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
LeonaBio, Inc. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.88 | 4.18 | 69.28 |
| Quick Ratio | 1.88 | 4.18 | 69.28 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $41.95 Million | $41.71 Million | $307.07 Million |
LeonaBio, Inc. - Advanced Valuation Insights
This section examines the relationship between LeonaBio, Inc.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.87 |
| Latest Market Cap to Assets Ratio | 0.90 |
| Asset Growth Rate (YoY) | 56.8% |
| Total Assets | $92.15 Million |
| Market Capitalization | $82.85 Million USD |
Valuation Analysis
Near Book Valuation: The market values LeonaBio, Inc.'s assets close to their book value (0.90x), suggesting investors view the company's assets at approximately fair value.
Rapid Asset Growth: LeonaBio, Inc.'s assets grew by 56.8% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for LeonaBio, Inc. (2018–2025)
The table below shows the annual total assets of LeonaBio, Inc. from 2018 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $92.15 Million | +56.78% |
| 2024-12-31 | $58.78 Million | -63.32% |
| 2023-12-31 | $160.25 Million | -37.93% |
| 2022-12-31 | $258.15 Million | -22.24% |
| 2021-12-31 | $332.01 Million | +18.76% |
| 2020-12-31 | $279.56 Million | +12671.27% |
| 2019-12-31 | $2.19 Million | -55.63% |
| 2018-12-31 | $4.93 Million | -- |
About LeonaBio, Inc.
LeonaBio, Inc., clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. Its product pipeline includes ATH-1105 for the treatment of amyotrophic lateral sclerosis, which is in phase 1 clinical trial; ATH-1020 for the treatment of neurodegenerative diseases, which is phase 1 clinical trial, as well as early compounds whic… Read more